HER2-Low Breast Cancer: DESTINY or Good Science?
HTML-код
- Опубликовано: 10 янв 2024
- This informative video sheds light on the nuances of HER2 biomarkers in breast cancer, exploring the critical distinctions between HER2 positive, negative, and the newly recognized HER2-Low category.
Embark on a journey through the history of HER2, from its discovery in the 1980s to the present, where FDA-approved treatments like trastuzumab (Herceptin) and trastuzumab-deruxtecan (ENHERTU) are making significant strides in patient care. Dr. Esteva discusses the pivotal DESTINY B04 clinical trial and its role in shaping the future of breast cancer treatment, highlighting the science behind the success of innovative therapies, including the concept of antibody-drug conjugates for HER2-positive and HER2-Low breast cancer.
Disclaimer: This video presents my views and perspectives, which are not necessarily representative of the opinions of my associated employers or institutions. The content provided herein is intended solely for informational purposes and should not be construed as medical advice. I endeavor to ensure the accuracy and timeliness of the information contained in this video. However, for personalized medical advice and guidance, it is recommended to seek consultation with a qualified healthcare professional.
Keywords: HER2-Low Breast Cancer, HER2 Biomarkers, Trastuzumab, Herceptin, ENHERTU, FDA Approval, DESTINY B04, Oncology, Breast Cancer Treatment, Antibody-Drug Conjugates, Medical Oncology
Hashtags: #HER2Low, #BreastCancerAwareness, #OncologyInnovation, #Trastuzumab, #ENHERTU
#CancerTreatment, #HER2Positive, #MedicalOncology
#CancerResearch, #DESTINYB04, #DESTINYB06
For more content on cancer treatment updates, please visit my website: www.cancertreatmentupdates.com and subscribe to my RUclips channel: / @cancertreatmentupdates
Follow me:
Instagram / dresteva
Facebook profile.php?...
Twitter (X) / cancerrxupdates
TikTok. / dresteva
LinkedIn / franciscoesteva
Google Scholar: scholar.google.com/citations?...
RUclips / @cancertreatmentupdates 
Наука
Thank you for the enhurtu update! I had stage 1 with multiple tumors. Some with her2 +1, some with her2 +2 , and one was her2 0, so I've been following the entertu story closely.
Thank you for your comment.
Great explanation
Thank you for your comment. I am glad you found the educational content helpful.
Please Dr Francisco if you read my message and let me know if there’s a good oncologist in California and Orange County thank you
I hope you have found a good oncologist in California.
What is fish test for cancer
Fluorescence in situ hybridization (FISH) is a method to detect gene amplification.
Fluorescence in situ hybridization (FISH) is a laboratory technique to detect amplification of certain genes. For example, in breast cancer we want to know if the her2 gene is amplified. In other tumor types we look for amplification of other genes. Research has shown that amplification of some genes leads to worse prognosis, and in some cases we can use those genetic alterations as therapeutic targets.
I diagnose 2020 withcarcinoma breast cancer I refuse to get chemo. I was with tamoxifen A year and a half and then now I am taking anastrozole for 2 1/2 years. am hoping in 2024 to have another option not Kimmo something Less chemical if Anybody know a good oncologist in California, please let me know thank you
Thank you for your comment. I am glad you found the educational content helpful. I can’t provide medical advice. The content of this video is for educational purposes only.
The effect is the same weather its intravenous or systemic. There is always a side effect. ❤